Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 22, 2017, Pages 5731-5736

  Irukayama Tomobe, Yoko ^a   Ogawa, Yasuhiro ^a   Tominaga, Hiromu ^a   Ishikawa, Yukiko ^a   Hosokawa, Naoto ^a   Ambai, Shinobu ^a   Kawabe, Yuki ^a   Uchida, Shuntaro ^a   Nakajima, Ryo ^a   Saitoh, Tsuyoshi ^a   Kanda, Takeshi ^a   Vogt, Kaspar ^a   Sakurai, Takeshi ^a   Nagase, Hiroshi ^a   Yanagisawa, Masashi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Electroencephalography; Electromyography; Excessive daytime sleepiness; G protein coupled receptors; Neuropeptide

Indexed keywords

ATAXIN 3; N ETHYL 2 [N (6 METHOXY 3 PYRIDINYL) 2 METHYLBENZENESULFONAMIDO] N (3 PYRIDINYLMETHYL)ACETAMIDE; OPIATE AGONIST; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; SUVOREXANT; UNCLASSIFIED DRUG; YNT 185; HCRT PROTEIN, MOUSE; HCRTR1 PROTEIN, MOUSE; HCRTR2 PROTEIN, MOUSE; OREXIN; OREXIN RECEPTOR; WAKEFULNESS PROMOTING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BODY TEMPERATURE; BRAIN ELECTROPHYSIOLOGY; BRAIN SLICE; CALCIUM CELL LEVEL; CATAPLEXY; CIRCADIAN RHYTHM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DESENSITIZATION; DOSE RESPONSE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; FEMALE; GENETIC TRANSFECTION; GLUCOSE METABOLISM; INSULIN RESISTANCE; MALE; MEMBRANE STEADY POTENTIAL; MOUSE; NARCOLEPSY; NONHUMAN; NONREM SLEEP; PRIORITY JOURNAL; PROTEIN EXPRESSION; REM SLEEP; REPEATED DRUG DOSE; SLEEP WAKING CYCLE; WAKEFULNESS; AGONISTS; ANIMAL; C57BL MOUSE; CIRCADIAN RHYTHM SLEEP DISORDER; DISEASE MODEL; DRUG EFFECT; GENETICS; HYPOTHALAMUS; KNOCKOUT MOUSE; METABOLISM; PATCH CLAMP TECHNIQUE; SLEEP;

ANIMALS; CATAPLEXY; DISEASE MODELS, ANIMAL; HYPOTHALAMUS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NARCOLEPSY; OREXIN RECEPTORS; OREXINS; PATCH-CLAMP TECHNIQUES; SLEEP; SLEEP DISORDERS, CIRCADIAN RHYTHM; WAKEFULNESS; WAKEFULNESS-PROMOTING AGENTS;

EID: 85020029560     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1700499114     Document Type: Article

References (31)

1. Sakurai T, et al. (1998) Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573-585.
2. Chemelli RM, et al. (1999) Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 98:437-451.
3. Peyron C, et al. (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18:9996-10015.
4. Cox CD, et al. (2010) Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1, 3-benzoxazol-2-yl)-7-methyl-1, 4-diazepan-1-yl][5-methyl-2-(2H-1, 2, 3-triazol-2-yl)phenyl] methanone (MK-4305) for the treatment of insomnia. J Med Chem 53:5320-5332.
5. Uslaner JM, et al. (2013) Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci Transl Med 5:179ra44.
6. Lin L, et al. (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98:365-376.
7. Sateia MJ (2014) International classification of sleep disorders-third edition: Highlights and modifications. Chest 146:1387-1394.
8. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39-40.
9. Peyron C, et al. (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991-997.
10. Thannickal TC, et al. (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27:469-474.
11. Scammell TE (2015) Narcolepsy. N Engl J Med 373:2654-2662.
12. Hara J, et al. (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, obesity. Neuron 30:345-354.
13. Tabuchi S, et al. (2014) Conditional ablation of orexin/hypocretin neurons: A new mouse model for the study of narcolepsy and orexin system function. J Neurosci 34:6495-6509.
14. Mieda M, et al. (2004) Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy inmice. Proc Natl Acad Sci USA 101:4649-4654.
15. Fujiki N, Yoshida Y, Ripley B, Mignot E, Nishino S (2003) Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 26:953-959.
16. Mochizuki T, et al. (2011) Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice. Proc Natl Acad Sci USA 108:4471-4476.
17. Hasegawa E, Yanagisawa M, Sakurai T, Mieda M (2014) Orexin neurons suppress narcolepsy via 2 distinct efferent pathways. J Clin Invest 124:604-616.
18. Willie JT, et al. (2003) Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: Molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 38:715-730.
19. Nagahara T, et al. (2015) Design and synthesis of non-peptide, selective Orexin receptor 2 agonists. J Med Chem 58:7931-7937.
20. Malherbe P, et al. (2009) Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br J Pharmacol 156:1326-1341.
21. Scammell TE, Willie JT, Guilleminault C, Siegel JM; International Working Group on Rodent Models of Narcolepsy (2009) A consensus definition of cataplexy in mouse models of narcolepsy. Sleep 32:111-116.
22. Oishi Y, et al. (2013) Role of themedial prefrontal cortex in cataplexy. J Neurosci 33:9743-9751.
23. Fujiki N, et al. (2006) Sex difference in body weight gain and leptin signaling in hypocretin/orexin deficient mouse models. Peptides 27:2326-2331.
24. Funato H, et al. (2009) Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab 9:64-76.
25. Shiuchi T, et al. (2009) Hypothalamic orexin stimulates feeding-associated glucose utilization in skeletal muscle via sympathetic nervous system. Cell Metab 10:466-480.
26. Tsuneki H, et al. (2015) Hypothalamic orexin prevents hepatic insulin resistance via daily bidirectional regulation of autonomic nervous system in mice. Diabetes 64:459-470.
27. Tsuneki H, et al. (2016) Nighttime administration of nicotine improves hepatic glucose metabolism via the hypothalamic orexin system in mice. Endocrinology 157:195-206.
28. Black SW, Schwartz MD, Chen TM, Hoener MC, Kilduff TS (October 18, 2016) Trace amine-associated receptor 1 agonists as narcolepsy therapeutics. Biol Psych, 10.1016/j. biopsych.2016.10.012.
29. Black SW, et al. (2014) GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy. J Neurosci 34:6485-6494.
30. Lazarus M, Huang ZL, Lu J, Urade Y, Chen JF (2012) How do the basal ganglia regulate sleep-wake behavior Trends Neurosci 35:723-732.
31. Rudick RA, Zirretta DK, Herndon RM (1982) Clearance of albumin from mouse subarachnoid space: A measure of CSF bulk flow. J Neurosci Methods 6:253-259.